Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KMT2C mutation
i
Other names:
MLL3, KMT2C, Lysine Methyltransferase 2C, Histone-Lysine N-Methyltransferase 2C, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 3, Lysine (K)-Specific Methyltransferase 2C, Histone-Lysine N-Methyltransferase, H3 Lysine-4 Specific, Myeloid/Lymphoid Or Mixed-Lineage Leukemia 3, Histone-Lysine N-Methyltransferase MLL3, Lysine N-Methyltransferase 2C, ALR-Like Protein, KLEFS2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
58508
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
KMT2C mutation
Colorectal Cancer
KMT2C mutation
Colorectal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
KMT2C mutation
Solid Tumor
KMT2C mutation
Solid Tumor
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
KMT2C mutation
Non Small Cell Lung Cancer
KMT2C mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
KMT2C mutation
Hepatocellular Cancer
KMT2C mutation
Hepatocellular Cancer
PD1 inhibitor + lenvatinib
Sensitive: C3 – Early Trials
PD1 inhibitor + lenvatinib
Sensitive
:
C3
PD1 inhibitor + lenvatinib
Sensitive: C3 – Early Trials
PD1 inhibitor + lenvatinib
Sensitive
:
C3
KMT2C mutation
Renal Cell Carcinoma
KMT2C mutation
Renal Cell Carcinoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
KMT2C mutation
Melanoma
KMT2C mutation
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
KMT2C mutation
Bladder Cancer
KMT2C mutation
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login